Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Michael Birrer

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Birrer, Michael

Item TypeName
Academic Article Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
Concept Antineoplastic Agents
Concept Antineoplastic Agents, Phytogenic
Academic Article A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Academic Article Clear cell cancer of the ovary.
Academic Article Targeting the Nuclear Import Receptor Kpn?1 as an Anticancer Therapeutic.
Academic Article Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Academic Article Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
Academic Article Novel therapeutic targets.
Academic Article Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Academic Article A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
Academic Article Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents.
Academic Article Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
Academic Article Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Academic Article Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Academic Article Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
Academic Article Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
Academic Article Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
Academic Article Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
Academic Article Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Academic Article Ovarian cancer: targeting the untargetable.
Academic Article Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Academic Article Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Academic Article CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Academic Article Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
Academic Article Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Academic Article Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors.
Academic Article Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
Academic Article Growth factors and other targets for rational application as intervention agents.
Academic Article Use of transcription factors as agents and targets for drug development.
Academic Article The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
Academic Article Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cells.
Academic Article Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
Academic Article Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Academic Article Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.
Academic Article Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Academic Article Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Academic Article DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Academic Article Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.

Search Criteria
  • Antineoplastic Agents